Ahmed Salah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmed Salah has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Abeer Ahmed Elmalah
Department of Cardiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
1 shared publication Alberto Hendler
1 shared publication- Alex Blatt
Department of Cardiology, Assaf Harofeh Medical Center, Zerifin, Israel
1 shared publication - Alexandre Boyer
Medical Intensive Care Unit, CHU Bordeaux, France
1 shared publication - Bassem Mohamed Abdel Hady
Department of Cardiology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
1 shared publication - Djillali Annane
Critical Care Department, Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris, 104. Boulevard Raymond Poincaré, Garches, Ile de France, France, 92380
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 21 (1) , em556
Relation between homocysteine-to-adropin ratio and severity of coronary artery disease
Purpose: This study aimed to uncover if homocysteine (Hcy) adropin balance expressed by homocysteine/adropin ratio (HAR) is related to severity of disease in coronary artery disease (CAD) patients. Materials & Methods: The present cross-sectional study 50 consecutive patients with low/intermediate CAD severity and other 50 patients with severe CAD. Hcy and adropin levels were assessed using commercially available kits. Results: Patients with low/moderate severity CAD expressed significantly lower HAR. According to HAR, all patients were classified into those with low HAR (<median) and high HAR (≥HAR). Comparison between these subgroups revealed that patients with low HAR had significantly lower number of affected vessels and lower SYNTAX score. Also, it was found that HAR is correlated with SYNTAX scores in all patients and in patients with severe CAD. Conclusions: Hcy and adropin levels are interlinked, HAR can effectively distinguish severe from non-severe CAD.
- 1 January 2024
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 21 (1) , em556
Open AccessRelation between homocysteine-to-adropin ratio and severity of coronary artery disease
Purpose: This study aimed to uncover if homocysteine (Hcy) adropin balance expressed by homocysteine/adropin ratio (HAR) is related to severity of disease in coronary artery disease (CAD) patients. Materials & Methods: The present cross-sectional study 50 consecutive patients with low/intermediate CAD severity and other 50 patients with severe CAD. Hcy and adropin levels were assessed using commercially available kits. Results: Patients with low/moderate severity CAD expressed significantly lower HAR. According to HAR, all patients were classified into those with low HAR (<median) and high HAR (≥HAR). Comparison between these subgroups revealed that patients with low HAR had significantly lower number of affected vessels and lower SYNTAX score. Also, it was found that HAR is correlated with SYNTAX scores in all patients and in patients with severe CAD. Conclusions: Hcy and adropin levels are interlinked, HAR can effectively distinguish severe from non-severe CAD.
- 1 July 2006
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 44 (07) , 309-318
Glucocorticoid treatment in patients with septic shock: effects on vasopressor use and mortality
Corticosteroids were proposed for the treatment of sepsis as early as 1940. Several RCTs cast serious doubts on the usefulness of high dose corticosteroids and doubt still persists regarding the efficacy of replacement therapy. Adrenal insufficiency (non-responders to the 250 microg corticotropin test: increase in cortisol < 9 microg/dl) is present in about half of patients with septic shock and is associated with higher rates of refractory hypotension and mortality. Peripheral glucocorticoid resistance, which may even occur more frequently, can be easily assessed at bedside using skin tests. Cortisol antagonizes the migration of inflammatory cells, the synthesis or action of virtually all proinflammatory mediators, promotes virtually all anti-inflammatory components and enhances humoral immunity by means of transcriptional interference between its receptor and both AP-1 and NF-kappaB. Cortisol mediates cardiovascular tolerance to endotoxin and the maintenance of vascular sensitivity to catecholamines. Low doses (about 300 mg daily for 5 days or more) of hydrocortisone increase vasoconstrictor response to catecholamines in animals, in healthy volunteers challenged with LPS and in several RCTs. Hydrocortisone also increases arterial pressure and decreases the duration of shock. A meta-analysis of all available clinical controlled studies showed a reduction in 28 days, all-cause mortality with glucocorticoids (RR = 0.88, 95% CI: 0.78 - 1.00; p = 0.04). However, there was a significant heterogeneity across the trials (p = 0.006). On the other hand, analysis of studies where low doses of glucocorticoids were given for prolonged periods showed a 24% reduction in the risk of all-cause mortality at 28 days in treated patients (RR = 0.76, 95% CI: 0.64 - 0.90; p = 0.002) without heterogeneity across the trials (p = 0.28). In conclusion, in severe sepsis, high doses of corticosteroids should not be given. Septic shock should be treated with a replacement dose of hydrocortisone.
- 1 July 2006
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 44 (07) , 309-318
Glucocorticoid treatment in patients with septic shock: effects on vasopressor use and mortality
Corticosteroids were proposed for the treatment of sepsis as early as 1940. Several RCTs cast serious doubts on the usefulness of high dose corticosteroids and doubt still persists regarding the efficacy of replacement therapy. Adrenal insufficiency (non-responders to the 250 microg corticotropin test: increase in cortisol < 9 microg/dl) is present in about half of patients with septic shock and is associated with higher rates of refractory hypotension and mortality. Peripheral glucocorticoid resistance, which may even occur more frequently, can be easily assessed at bedside using skin tests. Cortisol antagonizes the migration of inflammatory cells, the synthesis or action of virtually all proinflammatory mediators, promotes virtually all anti-inflammatory components and enhances humoral immunity by means of transcriptional interference between its receptor and both AP-1 and NF-kappaB. Cortisol mediates cardiovascular tolerance to endotoxin and the maintenance of vascular sensitivity to catecholamines. Low doses (about 300 mg daily for 5 days or more) of hydrocortisone increase vasoconstrictor response to catecholamines in animals, in healthy volunteers challenged with LPS and in several RCTs. Hydrocortisone also increases arterial pressure and decreases the duration of shock. A meta-analysis of all available clinical controlled studies showed a reduction in 28 days, all-cause mortality with glucocorticoids (RR = 0.88, 95% CI: 0.78 - 1.00; p = 0.04). However, there was a significant heterogeneity across the trials (p = 0.006). On the other hand, analysis of studies where low doses of glucocorticoids were given for prolonged periods showed a 24% reduction in the risk of all-cause mortality at 28 days in treated patients (RR = 0.76, 95% CI: 0.64 - 0.90; p = 0.002) without heterogeneity across the trials (p = 0.28). In conclusion, in severe sepsis, high doses of corticosteroids should not be given. Septic shock should be treated with a replacement dose of hydrocortisone.